Clinical trial
Antineoplaston Therapy in Treating Patients With Primary Central Nervous System…
NCT00003505 · Burzynski Research Institute, Other · Withdrawn
Key facts
| NCT number | NCT00003505 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Primary Central Nervous System Lymphoma |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Central Nervous System Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | antineoplaston A10, antineoplaston AS2-1, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy |
| Enrollment | 0 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: